Indianapolis-based Lilly is testing its weight loss drug Zepbound to treat addiction, while Meta outages affected more than ...

The digital health company Noom announced Thursday that it is expanding its weight-loss drug offerings to include pills, ...

Direct-to-consumer health and wellness company Ro will now offer access to lower-priced, single-dose vials of weight loss ...

With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is ...

Eli Lilly and Co. will begin studies to see if its blockbuster weight-loss medicines are also effective at controlling addictive behaviors like alcohol abuse, smoking and drug addiction, Chief ...

Ozempic and other GLP-1 drugs have surged in popularity, dominating U.S. medication spending in 2023 for their effectiveness in managing diabetes and promoting weight loss. As demand grows, promising ...

The NHS will deny 90 per cent of eligible obese patients the “King Kong” of weight loss jabs, citing budget pressures ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Millions of Americans who have obesity could gain insurance coverage for drugs like Wegovy if the Trump administration allows ...

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...

Chinese biotech Laekna Therapeutics on Wednesday announced a clinical collaboration with Eli Lilly (NYSE:LLY) to develop an obesity therapy that can avoid loss of muscle mass, a problem often ...

The pharmaceutical giant presented mid-stage trial data on the pill, muvalaplin ... so lifestyle changes such as diet or exercise have no effect, Ruth Gimeno, Lilly's group vice president for ...